The development of heart failure (HF) after acute myocardial infarction (AMI) is a prognostically important event, even in the context of early percutaneous coronary revascularization. The identification of patients at risk of developing HF remains an inexact science; even natriuretic peptides fail to provide accurate prognostication, in part, because of the fluctuations in plasma levels early after AMI. 1 In the search for novel biomarkers, much interest has centered on circulating microRNAs (miRNAs), primarily focusing on cardiac-enriched miRNAs as diagnostic markers of AMI. 2 Until recently, the prognostic value of circulating miRNAs in patients with AMI was poorly addressed.
Prognostic MicroRNAs After AMI
To the Editor:
The development of heart failure (HF) after acute myocardial infarction (AMI) is a prognostically important event, even in the context of early percutaneous coronary revascularization. The identification of patients at risk of developing HF remains an inexact science; even natriuretic peptides fail to provide accurate prognostication, in part, because of the fluctuations in plasma levels early after AMI. 1 In the search for novel biomarkers, much interest has centered on circulating microRNAs (miRNAs), primarily focusing on cardiac-enriched miRNAs as diagnostic markers of AMI. 2 Until recently, the prognostic value of circulating miRNAs in patients with AMI was poorly addressed.
Matsumoto et al 3 addressed the relevant question of whether circulating miRNAs may be used as predictors of prognosis after AMI. Plasma level of p53-responsive miR-192, miR-34a, and miR-194 were elevated in AMI patients who developed HF within the following year. In addition, miR-194 and miR-34a correlated with 1-year left ventricular end-diastolic dimension. Although of great scientific interest, this study has several limitations.
The first limitation relies on study design. The study comprised 2 phases with 2 cohorts of patients, but it is unclear from the Methods sections provided in the article and in the Online Data Supplement how patient selection was achieved. A first cohort consisting of 7 patients with HF and 7 patients with non-HF was used as derivation cohort. How were the 7 patients with HF selected from the 218 patients with HF of the whole study, and how were the 7 patients with non-HF selected from the 3942 patients with non-HF? This cohort of 2 groups of 7 patients is underpowered, even for a discovery phase using TaqMan arrays. Furthermore, the rationale for the imbalanced validation cohort of 21 patients with HF and 62 patients with non-HF requires clarification. This second cohort is not independent of the first cohort because patients were selected from the same population and is also underpowered. Small sample sizes and lack of statistical power likely explain, at least in part, why only 1 of 14 miRNAs differentially expressed between patients with HF and patients with non-HF in the derivation cohort could be validated in the validation cohort.
The second limitation relates to the authors' correlation of miR-194 and miR-34a with left ventricular end-diastolic dimension 1 year after AMI. We suggest it would have been more appropriate to consider the change in end-diastolic dimension between the convalescent phase of AMI and 1-year follow-up, rather than the absolute dimension at 1 year, to avoid potential bias caused by differences in LV dimensions at baseline.
Third, we question the conclusion that the 3 p53-responsive miRNAs identified in the present study may be useful for stratifying the risk of future ischemic HF events. This assertion is not supported by the data because no prediction analyses are reported (c-statistic, regression, and reclassification analyses).
Finally, the authors claim that no miRNAs have been established as predictors of ischemic HF that develop after AMI. This statement is incorrect. In a proof of concept study, Zile et al 4 reported association between changes in circulating levels of miR-29a in the early phase post AMI and left ventricular end-diastolic volume at 3-month follow-up. In a cohort of 216 patients with STsegment-elevation AMI, Eitel et al 5 showed plasma miR-133a to be a univariate predictor of major adverse cardiovascular events, defined as a composite of death, heart failure, and reinfarction within the 6 months after AMI. In a cohort of 510 patients with AMI, we reported that plasma levels of cardiac-enriched miR-208b and miR-499 measured in the few hours after chest pain onset are associated with ejection fraction at 4-month follow-up. 6 Recently, in 2 independent cohorts of patients with AMI, we have shown that plasma level of miR-150, a nonprototypical cardiac miRNA, is associated with left ventricular remodeling leading to HF. 7 The predictive value of miR-150 was superior to that of N-terminal pro-brain natriuretic peptide. None of these studies are cited by Matsumoto et al.
Overall, both the studies by Matsumoto 3 and others [4] [5] [6] [7] suggest that the potential of miRNAs as prognostic biomarker in this setting deserves further testing.
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